Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome
Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
This is an interventional drug study designed as a pilot for a randomized clinical trial,
aimed at assessing the effect of hydroxychloroquine on the incidence rate of thrombosis in
patients with primary antiphospholipid syndrome as the main outcome, as well as the safety of
hydroxychloroquine administration in this population. In addition, the effect of
hydroxychloroquine on antiphospholipid antibody titers will be assessed.